Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement.
Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956
